Navigation Links
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
Date:6/2/2008

bone marrow function, which is usually reversible and dose dependent, should be anticipated and is likely to increase the risk of infection, including severe sepsis. Administration of Clolar results in a rapid reduction of peripheral leukemia cells. Patients should be evaluated and monitored for signs and symptoms of tumor lysis syndrome and cytokine release (e.g., tachypnea, tachycardia, hypotension, pulmonary edema) that could develop into systemic inflammatory response syndrome (SIRS)/capillary leak syndrome, and organ dysfunction. Clolar should be discontinued immediately in the event of clinically significant signs or symptoms of SIRS or capillary leak syndrome.

The most common side effects seen after Clolar treatment, regardless of causality, were gastrointestinal tract symptoms, including vomiting, nausea, and diarrhea; hematologic effects including anemia, leukopenia, thrombocytopenia, neutropenia, and febrile neutropenia; and infection.

Liver and kidney function should be assessed prior to and during treatment with Clolar, as the liver is a target organ for Clolar toxicity and Clolar is excreted primarily through the kidneys. Concomitant use of medications known to induce hepatic toxicity should be avoided. Cardiac disorders, including tachycardia, pericardial effusion, and left ventricular systolic dysfunction, have been noted in up to 35% of pediatric patients treated with Clolar. However, the presence of these disorders in patients prior to Clolar administration and/or previous therapy or concurrent illness in patients receiving Clolar makes the etiology of these disorders unclear.

Clolar may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant and avoid breast feeding while receiving treatment with Clolar.

For more information about Clolar, please call 1-800-RX CLOLAR or visit http://www.CLOLAR.com
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015  The quality function within the medical ... meet quality standards at every stage of the product ... leaders also have the challenge of balancing quality and ... who don,t effectively balance these priorities risk funding and ... failure and regulatory scrutiny. For the third ...
(Date:3/27/2015)... March 27, 2015 Levi & Korsinsky announces ... (NASDAQ: OHRP ) concerning possible violations of federal ... the Company in connection with its study of the ... http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact Joseph E. Levi, Esq. ... by telephone at (212) 363-7500, toll-free: (877) 363-5972. ...
(Date:3/27/2015)... WINNIPEG , March 27, 2015 /PRNewswire/ - Medicure ... Board of Directors has approved the grant of an ... management company employees and consultants of the Company pursuant ... 181,070 are set to expire on the tenth anniversary ... expire on the third anniversary of the date of ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2
... Terumo Heart Inc., a wholly owned subsidiary of ... the worldwide expansion of its DuraHeart(TM) Left-Ventricular Assist System ... Arusoglu, MD and Michiel Morshuis, MD, cardiothoracic surgeons at ... Diabetes Center NRW, University Hospital of the Ruhr-University of ...
... select markets worldwideNATICK, Mass., May 19 Boston ... announced the launch of the platinum chromium TAXUS(R) ... worldwide. The TAXUS Element Stent features a ... stent applications and represents the Company,s third-generation drug-eluting ...
Cached Medicine Technology:Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System 2Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System 3Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System 4Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 2Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 3Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 4Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent 5
(Date:3/27/2015)... March 27, 2015 The Monogamy ... dating experts Samantha Sanderson and Jason Rogers has just ... of media attention. The commotion surrounding the course's launch ... him to publish an in-depth review of the new ... the men in their lives suddenly start pulling away ...
(Date:3/27/2015)... In her mid-forties and with a lifelong speech impediment ... arrived at JET Uniform & Supply for her ... The owners and staff at JET, which had partnered with ... jobs to challenged residents like Monica, were patient. , ... with the end in mind,” says Stephen Milaney, co-owner of ...
(Date:3/27/2015)... March 27, 2015 The federal court ... allege the statin medication increases the risk that a ... Inc.’s Motion to Dismiss four individual cases that had ... Management Order issued in the U.S. District Court, District ... that the dismissals were warranted because the plaintiffs in ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Bleeding ... patients undergoing percutaneous coronary intervention (PCI), resulting in ... observed a “risk-treatment paradox,” in which the highest-risk ... treatment are treated less often with bleeding avoidance ... Saint Luke’s Mid America Heart Institute asked the ...
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 Healthpointe ... Stanley G. Katz, M.D., is now treating knee and ... including Anaheim , Long Beach, and La Mirada. ... of acute knee and hip joint disorders as well ... Katz is passionate in returning his patients back to ...
Breaking Medicine News(10 mins):Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3
... TUESDAY, Jan. 4 (HealthDay News) -- President Barack Obama ... gives the U.S. Food and Drug Administration unprecedented powers ... The Food Safety Modernization Act, first passed by the ... represents the first significant strengthening of the nation,s food ...
... (HealthDay News) -- Levels of schooling may affect treatment and ... called acute ST-segment elevation myocardial infarction (STEMI), a new study ... attack, STEMI occurs when the coronary artery is totally blocked, ... In the new study, Dr. Rajendra H. Mehta, from ...
... N.C. A tiny light source and sensors at the ... to identify pre-cancerous cells in the lining of the esophagus. ... tested on patients during a clinical trial at the University ... promise of being a less invasive method for testing patients ...
... for the 2013 America,s Cup has been announced, a study ... smooth sailing. The study was published recently in the journal ... survey completed by sailors, researchers at Rhode Island Hospital have ... two types of boats -- dinghies (small boats with crews ...
... , TUESDAY, Jan. 4 (HealthDay News) -- Elderly people ... dementia, researchers have found. The new study included more ... dental examination and a psychiatric assessment. Compared with participants who ... or no teeth were much more likely to have experienced ...
... patients with osteoarthritis (OA) are likely not following standard ... Researchers noted physicians were prescribing medications for pain and ... weight loss plans or exercise programs to OA patients. ... January 2011 issue of Arthritis Care & Research ...
Cached Medicine News:Health News:Obama to Sign Bill to Improve U.S. Food Safety 2Health News:Obama to Sign Bill to Improve U.S. Food Safety 3Health News:Higher Education May Benefit Some Heart Attack Patients 2Health News:Detecting esophageal cancer with light 2Health News:Watch out for that boom 2Health News:Watch out for that boom 3Health News:Clinical practitioners not adhering to evidence-based guidelines for osteoarthritis 2Health News:Clinical practitioners not adhering to evidence-based guidelines for osteoarthritis 3
All Day Comfort for the Lower Body...
All Purpose, General Procedure Apron...
The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....
Features four-way apron closure for super adjustability to fit staff of all shapes and sizes. Top left and right shoulder closures allow adjustment of armhole size and chest area of apron for close a...
Medicine Products: